CD19-targeted chimeric antigen receptor (CAR) T-cell immunotherapy has demonstrated remarkable efficacy in managing relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) [1, 2]. The gene discussed is CD19; the disease is B-cell acute lymphoblastic leukemia.